BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

Reuters2025-03-13
BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty

** Brokerage Citi initiates coverage on eight small and mid-cap (SMid) biotechs - 89bio ETNB.O, Apogee Therapeutics APGE.O, Avidity Biosciences RNA.O, BioNTech 22UAy.DE, Kiniksa Pharmaceuticals KNSA.O, Kymera Therapeutics KYMR.O, Moderna MRNA.O and PTC Therapeutics PTCT.O

** Citi suggests SMid biotechs could be a good alternative to larger-cap stocks amid healthcare policy uncertainty

** Recent economic uncertainties, including increased tariffs and slowing economic growth, have "underscored the defensive attributes" of biotech and pharma stocks, brokerage says

** Higher-growth large caps such as Eli Lilly LLY.N and Vertex Pharma VRTX.O are likely able to absorb potential policy headwinds and "catalyst-driven" SMid biotechs are "insulated from macro uncertainties" - Citi

** YTD, S&P500 Health Care index .SPXHC has grown ~5%, NYSE Arca Pharmaceutical Index .DRG has gained ~6% and NASDAQ Biotechnology Index .NBI up ~3.3%

(Reporting by Mariam Sunny in Bengaluru)

((Mariam.ESunny@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment